Leslie Trigg - 31 Jul 2024 Form 4 Insider Report for ARYA Sciences Acquisition Corp IV

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 31 Jul 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 31 Jul 2024, 21:46:16 UTC
Prior SEC filing: 17 May 2024
Next SEC filing: 15 Aug 2024
Source filing: View source filing
Reporting owner signature: /s/ Samuel M. Cohn, attorney-in-fact

Key filing fact

Leslie Trigg filed Form 4 for ARYA Sciences Acquisition Corp IV on 31 Jul 2024.

Key facts

This page summarizes Leslie Trigg's Form 4 filing for ARYA Sciences Acquisition Corp IV.
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 31 Jul 2024, 21:46.

Change

Previous filing in this sequence was filed on 17 May 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ARYD transaction Derivative

Class B ordinary shares

Disposed to Issuer

Transaction value
Shares: -30,000
Change %: -100%
Price
Shares after: 0
Date: 31 Jul 2024
Ownership: Direct
Underlying class: Class A ordinary shares
Underlying amount: 30,000
Exercise price
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Leslie Trigg is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 1 footnote

Footnote F1

In connection with the Business Combination Agreement, dated February 13, 2024, by and among the Issuer, Adagio Medical Holdings, Inc. (f/k/a Aja HoldCo, Inc.) ("HoldCo"), Aja Merger Sub 1 ("Merger Sub 1"), Aja Merger Sub 2, Inc. ("Merger Sub 2") and Adagio Medical, Inc. ("Adagio") (the transactions contemplated thereby, the "Business Combination"), Merger Sub merged with and into the Issuer and Merger Sub 2 merged with and into Adagio, with each of the Issuer and Adagio becoming a wholly owned subsidiary of HoldCo, and the Reporting Person's ordinary shares of the Issuer were automatically converted into shares of common stock of HoldCo, par value $0.0001 per share, on a one-for-one basis.